It can be argued that Phase I is the lifeblood or new medicines. The UK’s Phase I representative body, the...
iOnctura awarded UK’s MHRA Innovation Passport for entry into the Innovative Licensing and Access Pathway (ILAP)....
All those in the pharmaceutical industry hoping to ease themselves into 2023 following the excitement of 2022 (...
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the...
Asthma is a chronic inflammatory disorder of the airways, characterised by reversible expiratory flow limitation and...
Findings from the UK’s world-leading human challenge study provide new insights into mild infections with SARS-CoV-2...
Like many European countries, Russia was markedly affected by COVID‐19.
The first step in ‘fighting’ the...
What do you want future working to look like? We have created...
The European Federation for Exploratory Medicines Development (EUFEMED)...
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) designation approval for their...
Specialists in clinical pharmacology – phase 1 and early phase 2 trials
